Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.22 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Behind the Scenes of Merck & Co's Latest Options Trends
 
Via Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
Is It Time to Buy July's Worst-Performing Dow Jones Stocks?
Most Dow stocks were winners last month, but not these. 
Via The Motley Fool
Topics Stocks
MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?
12 worst-performing large-cap stocks in the last week. Symbotic, Intel, Snap, Moderna, Mobileye, Pinterest, Arm, Entegris, Atlassian, MicroStrategy, New Oriental, and Western Digital. 
Via Benzinga
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
With an average yield above 7% at recent prices, these stocks could give your passive income stream a big boost. 
Via The Motley Fool
Decoding Merck & Co's Options Activity: What's the Big Picture?
 
Via Benzinga
Merck Analysts Slash Their Forecasts After Q2 Results
 
Via Benzinga
Analyzing Merck &amp; Co In Comparison To Competitors In Pharmaceuticals Industry
 
Via Benzinga
MarketBeat Week in Review – 7/29 - 8/2
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move 
Via MarketBeat
Topics Economy Stocks
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... 
Via Benzinga
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. 
Via InvestorPlace
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Moderna's vaccine magic is slowly losing its charm, as evidenced by the warning the company issued on Thursday but Ark reposed its faith in the company. 
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
 
Via Benzinga
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies. 
Via The Motley Fool
Nasdaq Tumbles Amid Decline In Tech Stocks: Greed Index Moves To 'Fear' Zone
Market sentiment declines as Fear & Greed index moves to 'Fear' zone. Dow Jones gains ahead of major earnings and Fed policy decision. 
Via Benzinga
Topics Economy Stocks
Merck (MRK) Q2 2024 Earnings Call Transcript
MRK earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting. 
Via Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
Via Benzinga
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip 
Via MarketBeat
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q2 2024
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
4 Stocks to Keep High on Your Buy List
Be ready for opportunities. 
Via The Motley Fool
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... 
Via Benzinga
Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short
Merck reported better-than-expected earnings on Tuesday. But the pharmaceutical giant's soft outlook could pressure Merck stock. 
Via Investor's Business Daily
Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide 'Turbo Boost' For Market? Analyst Weighs In
Wall Street is likely to tenaciously hold onto the slender optimism ahead of a slew of earnings from notable companies and the Federal Reserve’s two-day rate-setting meeting that gets underway on... 
Via Benzinga
Topics Economy Stocks
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.